News & Updates

Show Multimedia Only

Neoadjuvant olaparib feasible in BRCA-mutated ovarian cancer

23 May 2023 by

Neoadjuvant treatment with the PARP* inhibitor olaparib yielded encouraging outcomes in patients with BRCA-mutated ovarian cancer, with all participants completing two cycles of therapy followed by surgery in the NOW trial presented at SGO 2023.

23 May 2023

Eplontersen promising for hereditary ATTRv-PN

23 May 2023 by

Eplontersen, a ligand-conjugated antisense (LICA) investigational agent designed to reduce transthyretin (TTR) production or TTR protein, ably halts neuropathy progression and improves quality of life (QoL) in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) in the phase III NEURO-TTRansform trial.

23 May 2023

3-week azithromycin on par with 6-week doxycycline for treating MGD

22 May 2023

In the treatment of moderate-to-severe meibomian gland dysfunction (MGD), a 3-week course of oral azithromycin leads to outcomes that are similar to that achieved with a 6-week course of oral doxycycline, according to a study.

22 May 2023

LIBERTY-UC: Maintenance subcutaneous infliximab eases moderate-to-severe UC

22 May 2023 by

The subcutaneous infliximab formulation CT-P13 appears beneficial in the maintenance treatment of patients with moderately to severely active ulcerative colitis (UC), with data from the phase III study LIBERTY-UC showing that the drug outperforms placebo in multiple endpoints.

22 May 2023

Is long-term ustekinumab safe and effective in children with Crohn’s disease?

22 May 2023 by

Use of ustekinumab for up to 4 years in paediatric patients with Crohn’s disease (CD) shows similar efficacy, safety, pharmacokinetics (PK), and immunogenicity to that seen in adult patients, according to the results of the UniStar study long-term extension.

22 May 2023

Natriuretic response to acetazolamide predicts decongestion in acute heart failure

22 May 2023

A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.

22 May 2023

Dupilumab cuts exacerbations, improves lung function in paediatric asthma patients with high eosinophils

22 May 2023 by

In the post hoc analysis of data from the phase III LIBERTY ASTHMA VOYAGE study, the monoclonal antibody dupilumab reduced exacerbations and improved lung function in children aged between 6 and 11 years with moderate-to-severe asthma and baseline blood eosinophil count of ≥500 cells/μL.

22 May 2023

Panitumumab plus trifluridine-tipiracil confers survival advantage in RAS wild-type MCRC

21 May 2023

In the third-line treatment of patients with refractory RAS wild-type metastatic colorectal cancer (MCRC), use of panitumumab plus the standard-of-care trifluridine-tipiracil appears to prolong progression-free survival (PFS) when compared with trifluridine-tipiracil alone, according to data from a phase II study.